Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 10 | 10 | 10 | 10 | 10 |
| Accounts receivable | -39 | -7 | -28 | -14 | -9 |
| Accounts payable and accrued liabilities | 194 | -174 | -126 | 93 | 197 |
| Other Working Capital | 125 | -151 | -202 | 90 | 174 |
| Other Operating Activity | -2,429 | -1,034 | -2,243 | -869 | -687 |
| Operating Cash Flow | $-2,140 | $-1,356 | $-2,590 | $-692 | $-315 |
| Cash Flows From Investing Activities | |||||
| Purchase Sale Intangibles | N/A | N/A | 0 | -13 | N/A |
| Investing Cash Flow | $N/A | $N/A | $0 | $-13 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 0 | 740 | 10,000 | 0 | 2,813 |
| Other Financing Activity | 0 | -83 | -795 | 0 | 0 |
| Financing Cash Flow | $0 | $657 | $9,205 | $0 | $2,813 |
| Exchange Rate Effect | 143 | -130 | 10 | 58 | -7 |
| Beginning Cash Position | 8,270 | 9,099 | 2,474 | 3,122 | 745 |
| End Cash Position | 6,273 | 8,270 | 9,099 | 2,474 | 3,122 |
| Net Cash Flow | $-2,140 | $-699 | $6,615 | $-705 | $2,383 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,140 | -1,356 | -2,590 | -692 | -315 |
| Capital Expenditure | N/A | N/A | N/A | -13 | N/A |
| Free Cash Flow | -2,140 | -1,356 | -2,590 | -705 | -315 |